Rituximab (Moab C2b8 Anti Cd20, Chimeric)



Indications and Reactions:

Role Indications Reactions
Secondary
Chronic Lymphocytic Leukaemia 33.3%
Leukaemia 22.2%
Mantle Cell Lymphoma 11.1%
Non-hodgkin's Lymphoma 11.1%
Pyrexia 11.1%
Renal Failure Acute 11.1%
White Blood Cell Count Decreased 15.8%
Vomiting 14.1%
Pyrexia 12.0%
Febrile Neutropenia 9.2%
Neutropenia 9.2%
Lymphopenia 4.6%
Neutrophil Count Decreased 3.9%
Tachycardia 3.9%
Pneumonia 3.2%
Thrombocytopenia 3.2%
Sepsis 2.8%
Pulmonary Embolism 2.5%
Abdominal Pain 2.1%
Myelodysplastic Syndrome 2.1%
Staphylococcal Infection 2.1%
Unresponsive To Stimuli 2.1%
Weight Decreased 2.1%
Lymphocyte Count Decreased 1.8%
Pancytopenia 1.8%
Small Intestinal Obstruction 1.8%